CORDANI NICOLETTA

Villa, M., Malighetti, F., Villa, A., Cordani, N., Aroldi, A., Zambon, A., et al. (2026). Palbociclib targets β-catenin for degradation and synergizes with KRAS or ERK5 inhibition in colorectal cancer preclinical models. JOURNAL OF TRANSLATIONAL MEDICINE [10.1186/s12967-026-08420-7]. Detail

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer. NPJ PRECISION ONCOLOGY, 9(1) [10.1038/s41698-025-01088-0]. Detail

Crippa, V., Cordani, N., Villa, A., Malighetti, F., Villa, M., Sala, L., et al. (2025). Author Correction: Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer (npj Precision Oncology, (2025), 9, 1, (291), 10.1038/s41698-025-01088-0) [Altro] [10.1038/s41698-025-01114-1]. Detail

Malighetti, F., Villa, M., Villa, A., Pelucchi, S., Aroldi, A., Cortinovis, D., et al. (2025). Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 26(5) [10.3390/ijms26051943]. Detail

Cazzaniga, M., Pepe, F., Rossi, E., Coltelli, L., Beano, A., Valerio, M., et al. (2025). A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial. CLINICAL BREAST CANCER, 25(6), 560-565 [10.1016/j.clbc.2025.05.003]. Detail